These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17873612)

  • 1. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer.
    Mulder SA; van Leerdam ME; van Vuuren AJ; Francke J; van Toorenenbergen AW; Kuipers EJ; Ouwendijk RJ
    Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):878-82. PubMed ID: 17873612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
    Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.
    Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK
    Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
    Caviglia GP; Cabianca L; Fagoonee S; Gili FM
    Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination of faecal tests for the detection of colon cancer: a new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study.
    Parente F; Marino B; Ilardo A; Fracasso P; Zullo A; Hassan C; Moretti R; Cremaschini M; Ardizzoia A; Saracino I; Perna F; Vaira D
    Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1145-52. PubMed ID: 22735608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study.
    Shastri YM; Loitsch S; Hoepffner N; Povse N; Hanisch E; Rösch W; Mössner J; Stein JM
    Am J Gastroenterol; 2008 Jun; 103(6):1496-504. PubMed ID: 18510609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia.
    Shastri YM; Naumann M; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein JM
    Int J Cancer; 2006 Dec; 119(11):2651-6. PubMed ID: 16929517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
    Dollinger MM; Behl S; Fleig WE
    Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis.
    Tonus C; Sellinger M; Koss K; Neupert G
    World J Gastroenterol; 2012 Aug; 18(30):4004-11. PubMed ID: 22912551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Power of screening tests for colorectal cancer enhanced by high levels of M2-PK in addition to FOBT.
    Zaccaro C; Saracino IM; Fiorini G; Figura N; Holton J; Castelli V; Pesci V; Gatta L; Vaira D
    Intern Emerg Med; 2017 Apr; 12(3):333-339. PubMed ID: 28155016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of faecal protein biomarkers' diagnostic accuracy for colorectal advanced neoplasms: a systematic review and meta-analysis.
    Nasir Kansestani A; Zare ME; Tong Q; Zhang J
    Sci Rep; 2022 Feb; 12(1):2623. PubMed ID: 35173276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection.
    Hundt S; Haug U; Brenner H
    Ann Intern Med; 2009 Feb; 150(3):162-9. PubMed ID: 19189905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
    van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
    Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.
    Battaglia P; Baritono E; Remo A; Vendraminelli R; Conti A
    Tumori; 2014; 100(2):122-7. PubMed ID: 24852854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data].
    Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD
    Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests.
    Haug U; Hundt S; Brenner H
    Am J Gastroenterol; 2010 Mar; 105(3):682-90. PubMed ID: 19953091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A quantitative immunochemical fecal occult blood test for colorectal neoplasia.
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Leshno M; Niv Y
    Ann Intern Med; 2007 Feb; 146(4):244-55. PubMed ID: 17310048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Faecal biomarkers do not always identify pre-cancerous lesions in patients who present in primary care with bowel symptoms.
    Keenan J; Aitchison A; Leaman J; Pearson J; Frizelle F
    N Z Med J; 2019 Aug; 132(1501):48-56. PubMed ID: 31465327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of immunochemical fecal occult blood test to small colorectal adenomas.
    Morikawa T; Kato J; Yamaji Y; Wada R; Mitsushima T; Sakaguchi K; Shiratori Y
    Am J Gastroenterol; 2007 Oct; 102(10):2259-64. PubMed ID: 17617203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.
    Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
    Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.